These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 18557522)

  • 21. Identification of proteins of Propionibacterium acnes for use as vaccine candidates to prevent infection by the pig pathogen Actinobacillus pleuropneumoniae.
    Li L; Sun C; Yang F; Yang S; Feng X; Gu J; Han W; Langford PR; Lei L
    Vaccine; 2013 Oct; 31(45):5269-75. PubMed ID: 24051157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective efficacy of conjugate vaccines against experimental challenge with porcine Actinobacillus pleuropneumoniae.
    Byrd W; Harmon BG; Kadis S
    Vet Immunol Immunopathol; 1992 Nov; 34(3-4):307-24. PubMed ID: 1455686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New trends in innovative vaccine development against Actinobacillus pleuropneumoniae.
    Loera-Muro A; Angulo C
    Vet Microbiol; 2018 Apr; 217():66-75. PubMed ID: 29615259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of the role of antibodies to Actinobacillus pleuropneumoniae serovar 1 and 15 in the protection provided by sub-unit and live streptomycin-dependent pleuropneumonia vaccines.
    Tumamao JQ; Bowles RE; van den Bosch H; Klaasen HL; Fenwick BW; Blackall PJ
    Aust Vet J; 2004 Dec; 82(12):773-80. PubMed ID: 15648941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 10 of pigs vaccinated with bacterins consisting of A. pleuropneumoniae serotype 10 grown under NAD-rich and NAD-restricted conditions.
    van Overbeke I; Chiers K; Donne E; Ducatelle R; Haesebrouck F
    J Vet Med B Infect Dis Vet Public Health; 2003 Aug; 50(6):289-93. PubMed ID: 14629000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of recombinant ApxIV in serodiagnosis of Actinobacillus pleuropneumoniae infections, development and prevalidation of the ApxIV ELISA.
    Dreyfus A; Schaller A; Nivollet S; Segers RP; Kobisch M; Mieli L; Soerensen V; Hüssy D; Miserez R; Zimmermann W; Inderbitzin F; Frey J
    Vet Microbiol; 2004 Apr; 99(3-4):227-38. PubMed ID: 15066725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model.
    Chiang CH; Huang WF; Huang LP; Lin SF; Yang WJ
    Vaccine; 2009 Jul; 27(34):4565-70. PubMed ID: 19520199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine.
    Tonpitak W; Baltes N; Hennig-Pauka I; Gerlach GF
    Infect Immun; 2002 Dec; 70(12):7120-5. PubMed ID: 12438394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Both ApxI and ApxII of Actinobacillus pleuropneumoniae serotype 1 are necessary for full virulence.
    Boekema BK; Kamp EM; Smits MA; Smith HE; Stockhofe-Zurwieden N
    Vet Microbiol; 2004 May; 100(1-2):17-23. PubMed ID: 15135509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urease activity may contribute to the ability of Actinobacillus pleuropneumoniae to establish infection.
    Bossé JT; MacInnes JI
    Can J Vet Res; 2000 Jul; 64(3):145-50. PubMed ID: 10935879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selection of serotype-specific vaccine candidate genes in Actinobacillus pleuropneumoniae and heterologous immunization with Propionibacterium acnes.
    Lei L; Sun C; Lu S; Feng X; Wang J; Han W
    Vaccine; 2008 Nov; 26(49):6274-80. PubMed ID: 18835316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Actinobacillus pleuropneumoniae biofilms: Role in pathogenicity and potential impact for vaccination development.
    Hathroubi S; Loera-Muro A; Guerrero-Barrera AL; Tremblay YDN; Jacques M
    Anim Health Res Rev; 2018 Jun; 19(1):17-30. PubMed ID: 29110751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aerosol exposure of pigs to viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces antibodies in bronchoalveolar lining fluids and serum, and protects against homologous challenge.
    Hensel A; Stockhofe-Zurwieden N; Ganter M; Petzoldt K
    Vet Microbiol; 1995 Nov; 47(1-2):27-41. PubMed ID: 8604553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type IV fimbrial subunit protein ApfA contributes to protection against porcine pleuropneumonia.
    Sadilkova L; Nepereny J; Vrzal V; Sebo P; Osicka R
    Vet Res; 2012 Jan; 43(1):2. PubMed ID: 22240397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals.
    Liu J; Chen X; Lin L; Tan C; Chen Y; Guo Y; Jin M; Guo A; Bei W; Chen H
    Vaccine; 2007 Nov; 25(44):7696-705. PubMed ID: 17767980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nasal immunization with M cell-targeting ligand-conjugated ApxIIA toxin fragment induces protective immunity against Actinobacillus pleuropneumoniae infection in a murine model.
    Park J; Seo KW; Kim SH; Lee HY; Kim B; Lim CW; Kim JH; Yoo HS; Jang YS
    Vet Microbiol; 2015 May; 177(1-2):142-53. PubMed ID: 25818577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virulence factors of the swine pathogen Actinobacillus pleuropneumoniae.
    Tascón RI; Vázquez-Boland JA; Gutiérrez-Martín CB; Rodríguez-Barbosa JI; Rodríguez-Ferri EF
    Microbiologia; 1996 Jun; 12(2):171-84. PubMed ID: 8767702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state.
    Hensel A; Huter V; Katinger A; Raza P; Strnistschie C; Roesler U; Brand E; Lubitz W
    Vaccine; 2000 Jul; 18(26):2945-55. PubMed ID: 10825595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the protective efficacy of Actinobacillus pleuropneumoniae serotype 1 detoxified lipopolysaccharides or O-polysaccharide-protein conjugate in pigs.
    Rioux S; Girard C; Dubreuil JD; Jacques M
    Res Vet Sci; 1998; 65(2):165-7. PubMed ID: 9839897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construction and immunogencity of a DeltaapxIC/DeltaapxIIC double mutant of Actinobacillus pleuropneumoniae serovar 1.
    Lin L; Bei W; Sha Y; Liu J; Guo Y; Liu W; Tu S; He Q; Chen H
    FEMS Microbiol Lett; 2007 Sep; 274(1):55-62. PubMed ID: 17608699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.